MDXG earnings: next report 2026-07-29, real EPS beat/miss history, analyst consensus Buy, P/E 20.33. Updated 2026-07-23.
MiMedx Group (MDXG) Research Hub
MiMedx Group (MDXG) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.57 USD (-2.35%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 20.33, market cap 0.62B. This hub links to the full technical, earnings and options research available for MDXG.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.57 USD (-2.35%) |
| 52-week range | 3.58 USD – 4.73 USD |
| Trend regime | Range |
| 14-day RSI | 59.8 (Bullish) |
| Trailing P/E | 20.33 |
| Market cap | 0.62B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-29 |
Available research for MDXG
Covered Call on MDXG: how it works, illustrative setup around the real 4.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MDXG: how it works, illustrative setup around the real 4.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MDXG: how it works, illustrative setup around the real 4.57 USD price, max profit/loss, breakeven and when to use it. Educational.
MDXG technical analysis: range, last 4.57 USD, RSI 59.8, 52w range 3.58 USD–4.73 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MDXG in?
MiMedx Group (MDXG) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MDXG in an uptrend or downtrend?
As of 2026-09-11, MDXG is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MDXG's trailing P/E ratio?
MDXG's trailing P/E is 20.33, with a market cap of 0.62B. See the earnings research page for full valuation detail.
When does MDXG next report earnings?
MDXG is next scheduled to report earnings on 2026-07-29, with a consensus EPS estimate of -0.034 USD.